Preclinical Alzheimer's disease: A systematic review of the cohorts underlying the concept

Alzheimer's and Dementia

Volumn 13, Issue 4, 2017, Pages 454-467

  Epelbaum, Stéphane ^a   Genthon, Rémy ^a   Cavedo, Enrica ^a   Habert, Marie Odile ^a   Lamari, Foudil ^a   Gagliardi, Geoffroy ^a   Lista, Simone ^a,b   Teichmann, Marc ^a   Bakardjian, Hovagim ^a,b   Hampel, Harald ^a,b   Dubois, Bruno ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

Biomarker; Clinical trial; Cognition; Cohort; Cross sectional; Familial Alzheimer's disease; Longitudinal; Neuropathology; Preclinical Alzheimer's disease; Systematic review

Indexed keywords

ALZHEIMER DISEASE; CASE CONTROL STUDY; COGNITION; COGNITION ASSESSMENT; COGNITIVE DEFECT; COHORT ANALYSIS; CONCEPTUAL FRAMEWORK; DIAGNOSTIC PROCEDURE; DISEASE MARKER; FOLLOW UP; HUMAN; INFORMATION RETRIEVAL; MENTAL DETERIORATION; NEUROPATHOLOGY; NOMENCLATURE; PATHOPHYSIOLOGY; PRECLINICAL STUDY; PRIORITY JOURNAL; REVIEW; STANDARDIZATION; SYSTEMATIC REVIEW; CLASSIFICATION; METABOLISM; PRODROMAL SYMPTOM;

BIOLOGICAL MARKER;

ALZHEIMER DISEASE; BIOMARKERS; HUMANS; PRODROMAL SYMPTOMS; TERMINOLOGY AS TOPIC;

EID: 85014329946     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2016.12.003     Document Type: Review

References (74)

1. [1] Dubois, B., Hampel, H., Feldman, H.H., Scheltens, P., Aisen, P., Andrieu, S., et al. Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria. Alzheimers Dement 12 (2016), 292–323.
2. [2] Berg, L., McKeel, D.W. Jr., Miller, J.P., Storandt, M., Rubin, E.H., Morris, J.C., et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol 55 (1998), 326–335.
3. [3] Delaere, P., Duyckaerts, C., Masters, C., Beyreuther, K., Piette, F., Hauw, J.J., Large amounts of neocortical beta A4 deposits without neuritic plaques nor tangles in a psychometrically assessed, non-demented person. Neurosci Lett 116 (1990), 87–93.
4. [4] Hubbard, B.M., Fenton, G.W., Anderson, J.M., A quantitative histological study of early clinical and preclinical Alzheimer's disease. Neuropathol Appl Neurobiol 16 (1990), 111–121.
5. [5] Storandt, M., Grant, E.A., Miller, J.P., Morris, J.C., Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. Neurology 67 (2006), 467–473.
6. [6] Dubois, B., Feldman, H.H., Jacova, C., Hampel, H., Molinuevo, J.L., Blennow, K., et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 13 (2014), 614–629.
7. [7] Sperling, R.A., Aisen, P.S., Beckett, L.A., Bennett, D.A., Craft, S., Fagan, A.M., et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 (2011), 280–292.
8. [8] Tang, E.Y., Harrison, S.L., Errington, L., Gordon, M.F., Visser, P.J., Novak, G., et al. Current developments in dementia risk prediction modelling: an updated systematic review. PLoS One, 10, 2015, e0136181.
9. [9] Amieva, H., Le Goff, M., Millet, X., Orgogozo, J.M., Peres, K., Barberger-Gateau, P., et al. Prodromal Alzheimer's disease: successive emergence of the clinical symptoms. Ann Neurol 64 (2008), 492–498.
10. [10] Amieva, H., Mokri, H., Le Goff, M., Meillon, C., Jacqmin-Gadda, H., Foubert-Samier, A., et al. Compensatory mechanisms in higher-educated subjects with Alzheimer's disease: a study of 20 years of cognitive decline. Brain 137 (2014), 1167–1175.
11. [11] Jack, C.R. Jr., PART and SNAP. Acta Neuropathol 128 (2014), 773–776.
12. [12] Knopman, D.S., Jack, C.R. Jr., Wiste, H.J., Weigand, S.D., Vemuri, P., Lowe, V., et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 78 (2012), 1576–1582.
13. [13] Mormino, E.C., Betensky, R.A., Hedden, T., Schultz, A.P., Amariglio, R.E., Rentz, D.M., et al. Synergistic effect of beta-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol 71 (2014), 1379–1385.
14. [14] Mormino, E.C., Betensky, R.A., Hedden, T., Schultz, A.P., Ward, A., Huijbers, W., et al. Amyloid and APOE epsilon4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology 82 (2014), 1760–1767.
15. [15] Amariglio, R.E., Becker, J.A., Carmasin, J., Wadsworth, L.P., Lorius, N., Sullivan, C., et al. Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia 50 (2012), 2880–2886.
16. [16] Ayutyanont, N., Langbaum, J.B., Hendrix, S.B., Chen, K., Fleisher, A.S., Friesenhahn, M., et al. The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers. J Clin Psychiatry 75 (2014), 652–660.
17. [17] Sperling, R., Mormino, E., Johnson, K., The evolution of preclinical Alzheimer's disease: implications for prevention trials. Neuron 84 (2014), 608–622.
18. [18] Sperling, R.A., Rentz, D.M., Johnson, K.A., Karlawish, J., Donohue, M., Salmon, D.P., et al. The A4 study: stopping AD before symptoms begin?. Sci Transl Med, 6, 2014, 228fs13.
19. [19] Jicha, G.A., Abner, E.L., Schmitt, F.A., Kryscio, R.J., Riley, K.P., Cooper, G.E., et al. Preclinical AD Workgroup staging: pathological correlates and potential challenges. Neurobiol Aging 33 (2012), 622.e1–622.e16.
20. [20] Hyman, B.T., Phelps, C.H., Beach, T.G., Bigio, E.H., Cairns, N.J., Carrillo, M.C., et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 8 (2012), 1–13.
21. [21] Bateman, R.J., Xiong, C., Benzinger, T.L., Fagan, A.M., Goate, A., Fox, N.C., et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367 (2012), 795–804.
22. [22] WHO. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus. 1999 Geneva. Available at: http://apps.who.int/iris/bitstream/10665/66040/1/WHO_NCD_NCS_99.2.pdf. Accessed February 16, 2017.
23. [23] Hampel, H., Lista, S., Dementia: the rising global tide of cognitive impairment. Nat Rev Neurol 12 (2016), 131–132.
24. [24] Doody, R.S., Thomas, R.G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 370 (2014), 311–321.
25. [25] Salloway, S., Sperling, R., Fox, N.C., Blennow, K., Klunk, W., Raskind, M., et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 370 (2014), 322–333.
26. [26] Khachaturian, Z.S., Mesulam, M.M., Mohs, R.C., Khachaturian, A.S., Toward a consensus recommendation for defining the asymptomatic-preclinical phases of putative Alzheimer's disease?. Alzheimers Dement 12 (2016), 213–215.
27. [27] Sevigny, J., Chiao, P., Bussière, T., Weinreb, P.H., Williams, L., Maier, M., et al. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature 537 (2016), 50–56.
28. [28] Brier, M.R., Thomas, J.B., Snyder, A.Z., Wang, L., Fagan, A.M., Benzinger, T., et al. Unrecognized preclinical Alzheimer disease confounds rs-fcMRI studies of normal aging. Neurology 83 (2014), 1613–1619.
29. [29] Fortea, J., Vilaplana, E., Alcolea, D., Carmona-Iragui, M., Sanchez-Saudinos, M.B., Sala, I., et al. Cerebrospinal fluid beta-amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease. Ann Neurol 76 (2014), 223–230.
30. [30] Clark, L.R., Racine, A.M., Koscik, R.L., Okonkwo, O.C., Engelman, C.D., Carlsson, C.M., et al. Beta-amyloid and cognitive decline in late middle age: findings from the Wisconsin Registry for Alzheimer's Prevention study. Alzheimers Dement 12 (2016), 805–814.
31. [31] Donohue, M.C., Sperling, R.A., Salmon, D.P., Rentz, D.M., Raman, R., Thomas, R.G., et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol 71 (2014), 961–970.
32. [32] Langbaum, J.B., Hendrix, S.B., Ayutyanont, N., Chen, K., Fleisher, A.S., Shah, R.C., et al. An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease. Alzheimers Dement 10 (2014), 666–674.
33. [33] Lim, Y.Y., Maruff, P., Pietrzak, R.H., Ames, D., Ellis, K.A., Harrington, K., et al. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. Brain 137 (2014), 221–231.
34. [34] Lim, Y.Y., Snyder, P.J., Pietrzak, R.H., Ukiqi, A., Villemagne, V.L., Ames, D., et al. Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score. Alzheimers Dement 2 (2016), 19–26.
35. [35] Mielke, M.M., Wiste, H.J., Weigand, S.D., Knopman, D.S., Lowe, V.J., Roberts, R.O., et al. Indicators of amyloid burden in a population-based study of cognitively normal elderly. Neurology 79 (2012), 1570–1577.
36. [36] Pietrzak, R.H., Lim, Y.Y., Ames, D., Harrington, K., Restrepo, C., Martins, R.N., et al. Trajectories of memory decline in preclinical Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of ageing. Neurobiol Aging 36 (2015), 1231–1238.
37. [37] Pike, K.E., Ellis, K.A., Villemagne, V.L., Good, N., Chetelat, G., Ames, D., et al. Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study. Neuropsychologia 49 (2011), 2384–2390.
38. [38] van Harten, A.C., Smits, L.L., Teunissen, C.E., Visser, P.J., Koene, T., Blankenstein, M.A., et al. Preclinical AD predicts decline in memory and executive functions in subjective complaints. Neurology 81 (2013), 1409–1416.
39. [39] Jessen, F., Amariglio, R.E., van Boxtel, M., Breteler, M., Ceccaldi, M., Chetelat, G., et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement 10 (2014), 844–852.
40. [40] Mitchell, A.J., Beaumont, H., Ferguson, D., Yadegarfar, M., Stubbs, B., Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: meta-analysis. Acta Psychiatr Scand 130 (2014), 439–451.
41. [41] Jouvent, E., Reyes, S., De Guio, F., Chabriat, H., Reaction Time is a Marker of Early Cognitive and Behavioral Alterations in Pure Cerebral Small Vessel Disease. J Alzheimers Dis 47 (2015), 413–419.
42. [42] Rohrer, J.D., Nicholas, J.M., Cash, D.M., van Swieten, J., Dopper, E., Jiskoot, L., et al. Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. Lancet Neurol 14 (2015), 253–262.
43. [43] Di Stefano, F., Epelbaum, S., Coley, N., Cantet, C., Ousset, P.J., Hampel, H., et al. Prediction of Alzheimer's Disease Dementia: Data from the GuidAge Prevention Trial. J Alzheimers Dis 48 (2015), 793–804.
44. [44] Dubois, B., Feldman, H.H., Jacova, C., Dekosky, S.T., Barberger-Gateau, P., Cummings, J., et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6 (2007), 734–746.
45. [45] Hampel, H., Frank, R., Broich, K., Teipel, S.J., Katz, R.G., Hardy, J., et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov 9 (2010), 560–574.
46. [46] Morris, J.C., Roe, C.M., Grant, E.A., Head, D., Storandt, M., Goate, A.M., et al. Pittsburgh Compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 66 (2009), 1469–1475.
47. [47] Morris, J.C., Roe, C.M., Xiong, C., Fagan, A.M., Goate, A.M., Holtzman, D.M., et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 67 (2010), 122–131.
48. [48] Clark, C.M., Schneider, J.A., Bedell, B.J., Beach, T.G., Bilker, W.B., Mintun, M.A., et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 305 (2011), 275–283.
49. [49] Rinne, J.O., Wong, D.F., Wolk, D.A., Leinonen, V., Arnold, S.E., Buckley, C., et al. [(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid beta detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies. Acta Neuropathol 124 (2012), 833–845.
50. [50] Rabin, L.A., Smart, C.M., Crane, P.K., Amariglio, R.E., Berman, L.M., Boada, M., et al. Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. J Alzheimers Dis 48 Suppl 1 (2015), S63–S86.
51. [51] del Campo, M., Mollenhauer, B., Bertolotto, A., Engelborghs, S., Hampel, H., Simonsen, A.H., et al. Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomark Med 6 (2012), 419–430.
52. [52] Jagust, W.J., Landau, S.M., Koeppe, R.A., Reiman, E.M., Chen, K., Mathis, C.A., et al. The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015. Alzheimers Dement 11 (2015), 757–771.
53. [53] Toledo, J.B., Zetterberg, H., van Harten, A.C., Glodzik, L., Martinez-Lage, P., Bocchio-Chiavetto, L., et al. Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain 138 (2015), 2701–2715.
54. [54] Jack, C.R. Jr., Wiste, H.J., Weigand, S.D., Knopman, D.S., Mielke, M.M., Vemuri, P., et al. Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. Brain 138 (2015), 3747–3759.
55. [55] Dubois, B., Chupin, M., Hampel, H., Lista, S., Cavedo, E., Croisile, B., et al. Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease. Alzheimers Dement 11 (2015), 1041–1049.
56. [56] Hampel, H., Lista, S., Teipel, S.J., Garaci, F., Nistico, R., Blennow, K., et al. Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020. Biochem Pharmacol 88 (2014), 426–449.
57. [57] Lista, S., Khachaturian, Z.S., Rujescu, D., Garaci, F., Dubois, B., Hampel, H., Application of systems theory in longitudinal studies on the evolution and progression of Alzheimer's disease. Castrillo, J.I., Oliver, S.G., (eds.) Systems Biology of Alzheimer's Disease, 2016, Springer Science+Business Media, New York, 49–67.
58. [58] Chen, G., Levy, D., Contributions of the Framingham Heart Study to the Epidemiology of Coronary Heart Disease. JAMA Cardiol 1 (2016), 825–830.
59. [59] Mahmood, S.S., Levy, D., Vasan, R.S., Wang, T.J., The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. Lancet 383 (2014), 999–1008.
60. [60] Weiner, M.W., Aisen, P.S., Jack, C.R. Jr., Jagust, W.J., Trojanowski, J.Q., Shaw, L., et al., Alzheimer's Disease Neuroimaging Initiative. The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement 6 (2010), 202–211.e7.
61. [61] van der Flier, W.M., Pijnenburg, Y.A., Prins, N., Lemstra, A.W., Bouwman, F.H., Teunissen, C.E., et al. Optimizing patient care and research: the Amsterdam Dementia Cohort. J Alzheimers Dis 41 (2014), 313–327.
62. [62] Ellis, K.A., Bush, A.I., Darby, D., De Fazio, D., Foster, J., Hudson, P., et al., AIBL Research Group. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr 21 (2009), 672–687.
63. [63] Greenwood, P.M., Lambert, C., Sunderland, T., Parasuraman, R., Effects of apolipoprotein E genotype on spatial attention, working memory, and their interaction in healthy, middle-aged adults: results from the National Institute of Mental Health's BIOCARD study. Neuropsychology 19 (2005), 199–211.
64. [64] The Baltimore Longitudinal Study on Aging (BLSA). Available at: https://clinicaltrials.gov/ct2/show/NCT00233272. Accessed June 30, 2016.
65. [65] Dagley, A., LaPoint, M., Huijbers, W., Hedden, T., McLaren, D.G., Chatwal, J.P., et al. Harvard Aging Brain Study: dataset and accessibility. Neuroimage 144 (2017), 255–258.
66. [66] Roberts, R.O., Geda, Y.E., Knopman, D.S., Cha, R.H., Pankratz, V.S., Boeve, B.F., et al. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology 30 (2008), 58–69.
67. [67] Roberts, R.O., Cha, R.H., Knopman, D.S., Petersen, R.C., Rocca, W.A., Postmenopausal estrogen therapy and Alzheimer disease: overall negative findings. Alzheimer Dis Assoc Disord 20 (2006), 141–146.
68. [68] National Alzheimer's Coordinating Center (NACC). Available at: https://www.alz.washington.edu/cgibin/broker93?_service=naccnew9&_program=naccwww.pubrep1.sas&TYPEF=DISPLAYIDS. Accessed June 30, 2016.
69. [69] Snowdon, D.A., Kemper, S.J., Mortimer, J.A., Greiner, L.H., Wekstein, D.R., Markesbery, W.R., Linguistic ability in early life and cognitive function and Alzheimer's disease in late life. Findings from the Nun Study. JAMA 275 (1996), 528–532.
70. [70] Alcolea, D., Martínez-Lage, P., Sánchez-Juan, P., Olazarán, J., Antúnez, C., Izagirre, A., et al. Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease. Neurology 85 (2015), 626–633.
71. [71] Vos, S.J., Xiong, C., Visser, P.J., Jasielec, M.S., Hassenstab, J., Grant, E.A., et al. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol 12 (2013), 957–965.
72. [72] Sager, M.A., Hermann, B., La Rue, A., Middle-aged children of persons with Alzheimer's disease: APOE genotypes and cognitive function in the Wisconsin Registry for Alzheimer's Prevention. J Geriatr Psychiatry Neurol 18 (2005), 245–249.
73. [73] La Rue, A., Hermann, B., Jones, J.E., Johnson, S., Asthana, S., Sager, M.A., Effect of parental family history of Alzheimer's disease on serial position profiles. Alzheimers Dement 4 (2008), 285–290.
74. [74] Weintraub, S., Salmon, D., Mercaldo, N., Ferris, S., Graff-Radford, N.R., Chui, H., et al. The Alzheimer's Disease Centers’ Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Dis Assoc Disord 23 (2009), 91–101.